MedTrace Logo

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

NCT06492837 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-01-28

No results posted yet for this study

Summary

This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.

Conditions

Interventions

DRUG

Mosunetuzumab in combination with Zanubrutinib

Combinations of Mosunetuzumab and Zanubrutinib as salvage strategy in patients with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Marco Ladetto, Prof · Department of Translational Medicine of the Università degli Studi del Piemonte Orientale, Novara, Italy. AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.

  • Stefano Luminari, Prof · Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy. Hematology Unit of AUSL-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Reggio Emilia, Italy.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-23
Primary Completion
2028-09-15
Completion
2033-09-15

Countries

  • Australia
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492837 on ClinicalTrials.gov